Business
New Vice President of Operations in Asia
New Vice President of Operations in Asia.
About this update from Diaceutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0507V\n Diaceutics PLC\n 12 April 2021\n \n \n \n \n 12 April 2021\n \n \n \n \n \n Diaceutics PLC\n \n \n (\"Diaceutics\" or \"the Company\") \n \n \n \n \n \n New Vice President of Operations within the Asia Pacific region\n \n \n Appointment for Asia Pacific region to expand Diaceutics portfolio\n \n \n \n \n \n \n \n \n \n Diaceutics PLC\n \n , (\n AIM: DXRX), announces the appointment of Yvanka Gilliam as Vice President for the Asia Pacific region (APAC).\n \n \n \n \n \n \n In her new role, Yvanka will be responsible for managing business development and operations within the APAC region with a core focus on \n establishing key collaborations and strategic partnerships to drive growth and revenue. \n Her role will also include identifying innovative and creative services and solutions to help leverage the Company's platform DXRX and increase the offering. \n \n \n \n \n \n Yvanka has a strong track record managing the delivery of real-world insights for evaluation by regulators, payers and clinicians. Prior to joining Diaceutics, Yvanka\n worked with Kantar Health as a Senior Client Partner, Real World Evidence, where she developed and implemented global business planning strategies and conducted high-quality research. In recent years, Yvanka has also worked with IQVIA Asia Pacific in the Real World Insights Division and as a Senior Medical Science Liaison at AstraZeneca Pharmaceutical Corporation.\n \n \n \n \n \n Y\n vanka holds a doctorate degree in Pharmacy from The University of Michigan College of Pharmacy in Ann Arbor, a bachelor's degree in Biology and Chemistry from\n Grambling University in Louisiana\n and an MBA in International Business from Rutgers University Singapore. Yvanka's work has been \n \n published\n \n in the Annals of Oncology and the \n \n Journal\n \n of Clinical Oncology - an American Society of Clinical Oncology (ASCO) Journal.\n \n \n \n \n \n \n Peter Keeling, Chief Executive Officer of Diaceutics, said:\n \n \n \"Yvanka's appointment will strengthen\n \n \n Diaceutics' credentials as \n the market leader in the development and commercialisation of precision medicine diagnostics.\n \n \n \n As her 20-plus year career in pharma has been focused primarily on the Research and Development of innovative oncology c...